Exploring how nitrative stress affects hearing loss from cancer treatment
Targeting nitrative stress for treatment of cisplatin ototoxicity
This study is looking at how a certain type of stress in the body might cause hearing loss in cancer patients who are being treated with cisplatin, a common chemotherapy drug, and it hopes to find ways to protect their hearing while they receive treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wayne State University NIH-funded |
| Lab location | 1 site (Detroit, United States) |
| Project ID | NIH-10987035 on NIH RePORTER |
What this research studies
This research investigates the role of nitrative stress in causing hearing loss in patients treated with cisplatin, a common chemotherapy drug. It aims to understand how this stress alters protein signaling in the cochlea, leading to cell death and permanent hearing impairment. By focusing on a specific protein, LMO4, the study seeks to uncover the mechanisms behind cisplatin-induced ototoxicity and identify potential strategies to mitigate this side effect. The research involves detailed biochemical analyses and signaling pathway investigations to provide insights into preventing hearing loss in cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are receiving cisplatin and are at risk of developing hearing loss.
Not a fit: Patients who are not undergoing cisplatin treatment or those with pre-existing hearing loss unrelated to chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent hearing loss in cancer patients undergoing cisplatin therapy.
How similar studies have performed: Previous research has shown promise in targeting nitrative stress in other contexts, suggesting potential for success in this novel application.
Where this research is happening
Detroit, United States
- Wayne State University — Detroit, United States (Active)
Researchers
- Principal investigator: Jamesdaniel, Samson — Wayne State University
- Study coordinator: Jamesdaniel, Samson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.